Trial Profile
Evaluation of Effectiveness and Safety of Promus PREMIER in Routine Clinical Practice; A Multicenter, Phase-IV, Prospective Observational Study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 15 Sep 2021
Price :
$35
*
At a glance
- Drugs Everolimus (Primary)
- Indications Coronary artery disease; Coronary artery restenosis; Coronary disorders; Heart disorders; Myocardial ischaemia
- Focus Adverse reactions
- Acronyms IRIS-PREMIER REGISTRY
- 06 Sep 2021 Status changed from active, no longer recruiting to completed.
- 20 Jul 2016 Status changed from recruiting to active, no longer recruiting.
- 15 Jun 2016 Planned End Date changed from 1 Jun 2020 to 1 Jun 2021.